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reduced rosacea risk in diabetics at an
advanced disease stage. This is, to our
knowledge, a previously unreported
finding, but some residual confounding
or chance cannot entirely be
ruled out. Whether insulin enhances
this effect per se or whether it reflects
a proxy for disease severity remains
unclear.
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TO THE EDITOR
Dominant dystrophic epidermolysis
bullosa (DDEB) is a rare genetic blistering
skin disorder with no known cure. The
disorder is caused by mutations in the
COL7A1 gene leading to weakened
a1(VII) (collagen VII) homotrimers,
whose function is to knit epidermal
and dermal skin layers together
(Parente et al., 1991; McGrath et al.,
1993). Over 60 COL7A1 mutations
have been implicated in DDEB,
making this disorder, similar to
many other dominant disorders,
extremely heterogenous (Nakamura
et al., 2004).
A gene therapy strategy for DDEB
involving suppression of mutant
COL7A1 transcripts using allele-specific
RNA interference (RNAi) molecules tar-
geting a mutation site has been adopted
in vitro (Pendaries et al., 2012). This
informative study demonstrated potent
and specific RNAi-mediated allele-
specific suppression of a COL7A1
splice-site mutation in cells; similar
levels of RNAi specificity have been
obtained by others (Hickerson et al.,
2008; Lindahl et al., 2008; Atkinson
et al., 2011). In contrast, for many
COL7A1 mutations and indeed other
target genes, allele-specific RNAi
suppression has not been achieved (de
Yn˜igo-Mojado et al., 2011; Pendaries
et al., 2012 and Morgan et al.,
unpublished data).
Given the vast array of COL7A1
mutations implicated in DDEB, the
development of RNAi-mediated mutation-
specific therapies targeting each mutant
is not technically/economically feasible.
In this study, we have addressed the
substantial problem of DDEB-associated
mutational heterogeneity and have
tested four mutation-independent small
interfering RNAs (siRNAs; si1-si4) tar-
geting different regions of the COL7A1Accepted article preview online 6 June 2013; published online 11 July 2013
Abbreviations: DDEB, dominant dystrophic epidermolysis bullosa; NT, nontargeting negative control
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gene (Figure 1d). A single potent
mutation-independent suppressor in
conjunction with a replacement gene
designed to be refractory to suppression
represents a therapy for DDEB, which
corrects the primary genetic defect, but in
a mutation-independent manner.
The two elements of this dual-com-
ponent therapy for DDEB were evalu-
ated as follows: si1-si4 targeting
positions 733–753, 6,356–6,376, 5,384–
5,404, and 2,902–2,922 of the COL7A1
sequence (NM_000094), respectively,
and a nontargeting control siRNA (NT)
were tested (Supplementary Materials
and Methods online). In 24-well plates,
5 nM si1-si4 and control NT were
transfected into 1 105 keratinocytes,
HaCaTs (Boukamp et al., 1988). RNA
was isolated 24 hours after transfection
(Allen et al., 2008). COL7A1 RNA
levels were suppressed significantly by
si1-si4 by 65±9%, 50±13.5%,
71±8.7%, and 68±3.7%, respectively
(n¼ 4; Po0.001; Figure 1a). Short
hairpin RNA equivalents of si1, si3,
and si4 (sh1, sh3, and sh4) were gener-
ated (Brummelkamp et al., 2002), and
after transfection into immortalized
HaCaT cells significant suppression of
COL7A1 transcript levels of 73±3.4%,
57±2.4%, and 49±15%, respectively,
was demonstrated (n¼ 3; Po0.001;
Figure 1a).
Notably, suppression of COL7A1
transcript was also confirmed in primary
cells, normal human dermal fibroblast
primary cells, and significant suppres-
sion levels of 75±13.7%, 60±17.7%,
79±8.5%, and 77±12% were demon-
strated with si1-si4, respectively (n¼3;
Po0.001; Figure 1c). Similarly, in
HaCaT cells, suppression at the protein
level by the most efficient siRNA, si3,
was clearly visible by western blot-
ting 48 hours after RNAi transfection
(Figure 1b).
The most potent RNAi molecule,
si3, was investigated further for this
mutation-independent suppression and
replacement therapeutic strategy for
DDEB and a replacement COL7A1 gene
(R) was generated with altered degen-
erate nucleotides at the si3 target site
(Figure 2a). Alterations in codon usage
was minimized when designing R by
using conservative codon changes, and
thus expression levels would be opti-
mal. As the transcript expressed from R
contains six-nucleotide mismatches
(Figure 2a in red) at the si3 target site,
it was expected that, although R
encodes wild-type Collagen VII protein,
RNAi suppression by si3 should be
minimal or eliminated.
Indeed, when 0.6mg R and 1.25 nM of
si3 or NT were co-transfected in a
six-well plate into HEK293 cells, R
transcript was not suppressed signifi-
cantly by si3 (Supplementary Materials
and Methods online). In contrast, wild-
type COL7A1 RNA was suppressed
by 77±11% by si3 compared with
the non-targeting RNAi (NT) (n¼ 3;
Po0.001), and no expression of wild-
type COL7A1 RNA was observed in
untransfected cells (Figure 2b and c).
Similarly, at the protein level, replace-
ment Collagen VII protein was not
suppressed by si3, as evaluated by
western blotting, whereas the wild-type
protein was noticeably reduced (Figure
2b and c). Hence, we have clearly
demonstrated that R RNA is resistant to
suppression by si3, whereas wild-type
COL7A1 is potently suppressed by
B80%.
DDEB is a debilitating, untreatable
condition for which development of
gene therapies has been hampered by
1
0.8
0.6
***
***
***
***
***
***
***
si2
si2
***
***
***
***
1 403 682
N-terminus
si1 si4 si3 si2
C-terminus
8,3505,9355,8183,565 3,7603,136
N-terminus von Willebrand factor A domain
Triple-helical collagenous domains
‘Hinge’ region
C-terminus including Kunitz module
Cartilage matrix protein
Fibronectin III-like domain
Cysteine- and proline-rich region
8,835
sh3 si4
si4
si3
si3
sh1 sh4
290 kDa
165 kDa
145 kDa
NT si3
COL7A1
LAMA3
LAMB3
M
si1
si1
NT
NT
CO
L7
A1
 
m
R
N
A 
ex
pr
es
sio
n
CO
L7
A1
 
m
R
N
A 
ex
pr
es
sio
n
0.4
0.2
0
1
0.8
0.6
0.4
0.2
0
Figure 1. RNA interference (RNAi) suppression of COL7A1. Relative COL7A1 mRNA levels in HaCaT cells transfected with small interfering RNAs (siRNAs)
and short hairpin RNAs (shRNAs) (a) and siRNA-transfected normal human dermal fibroblast (NHDF) cells (c) compared with nontargeting negative control RNAi
(NT)-treated cells. Error bars represent SD. siRNA3 (si3) suppressed COL7A1 by 71±8.7% and 79±8.5% in HaCaTs and NHDFs, respectively, and by 57±2.4%
in shRNA format (sh3). (b) Western blot of collagen VII protein levels in medium isolated from si3 or NT-transfected HaCaT cells. Laminin 332 was used
as a loading control. Collagen VII and laminin 332 a3 (LAMA3) and b3 (LAMB3) chains are indicated. Collagen VII protein was visibly reduced in si3-treated cells
compared with NT-treated cells. (d) Collagen VII domain organization. Arrows represent the COL7A1 targets for si1-4. ***Po0.001. M, molecular weight.
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significant mutational heterogeneity
and the nature of the target tissue. Some
mutation-specific gene therapeutics
have been able to discriminate between
mutant and wild-type alleles and pro-
vide a potential nucleotide-based ther-
apy that does not require a replacement
gene, as the mutant allele is specifically
silenced and expression of the wild-type
allele is maintained (Pendaries et al.,
2012; Hu¨nefeld et al., 2013). However,
for many mutations, allele-specific
RNAi remains elusive. To circumvent
technical difficulties with designing
allele-specific suppressors together with
the cost burden of developing gene
therapies for every COL7A1 mutation,
a suppression and replacement gene
therapy (Millington-Ward et al., 1997)
has been developed for DDEB, which
corrects the primary defect but is
independent of mutation. In principle,
one therapy could treat all DDEB
patients irrespective of their underlying
COL7A1 mutation. If therapies are to
attract the investment required to
proceed to Phase I/II clinical trial,
developing widely applicable therapies
for rare orphan diseases such as DDEB
is crucial; exploiting fundamental
features of the genome, such as codon
redundancy, as adopted in the current
study in principle will facilitate this.
Furthermore, the inclusion of both
elements of this dual-component
therapeutic in a single vector would
further expedite progression toward
clinical trial. In terms of efficacy, there
is previous evidence in cells that
modulation of the ratio of mutant:wild-
type collagen VII (from 50:50 to 10:90)
improves the thermal stability of
collagen trimers, suggesting that in
principle achieving levels of
suppression of the mutant such as that
in the current study (70–80%) together
with potent replacement should provide
beneficial effects (Fritsch et al., 2009).
However, additional challenges for
DDEB include a requirement for novel
delivery systems to enable dissemina-
tion of the therapeutic thoughout the
body and longevity of therapeutic
effects. In this regard, viral and nonvi-
ral vectors and local versus systemic
administration of therapies are being
considered but require further develop-
ment (Has and Kiritsi, 2013; Hu¨nefeld
et al., 2013).
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TO THE EDITOR
Dermatomyositis (DM) is a rare systemic
autoimmune disease characterized by
inflammation of the skin and muscle.
Skin rash in DM may precede the onset
of muscle disease by months to years,
and in some cases overt muscle disease
may remain mild or never occur.
DM skin disease manifests in varied ways
including facial edema, pink to violac-
eous patches on the eyelids (heliotrope
sign), violaceous scaly plaques with
atrophy on the shoulders and hips,
violaceous atrophic scaling papules on
the interphalangeal joints (Gottron’s
papules), and prominent nailfold telan-
giectasias. However, these findings are
variably present, and DM skin disease
can share clinical features with cuta-
neous lupus, overlap connective tissue
disease syndromes, UV light–induced
reactions, and psoriasis (Sontheimer,
2002), often creating diagnostic
difficulty at early presentation.
Psoriasis is an inflammatory skin
disease most commonly characterized
by well-demarcated plaques with
micaceous scales. Histopathologically,
psoriasis displays epidermal acanthosis,
confluent parakeratosis, subcorneal
neutrophils, and thinning of the supra-
papillary plate. In contrast, DM is
characterized by an interface dermatitis
with a superficial perivascular infiltrate,
and dermal mucin deposition. However,
DM patients often present with erythe-
matous scaly plaques in the scalp or
on extremities, which can be clinically
confused with psoriasis. In addition,
many skin biopsies of DM can actually
show minimal to no interface dermatitis,
and have evidence of neutrophilic inflam-
mation (Ito et al., 1995; Caproni et al.,
2004), perivascular dermatitis, and even
epidermal hyperplasia not dissimilar to
that seen in psoriasis.
Molecular profiling has widely been
used to aid the diagnosis of cancer
patients since the publication of land-
mark work by Golub et al. (1999). It
has also been applied in autoimmune
diseases such as systemic lupus
erythematosus for similar purposes
(Chaussabel et al., 2008). In this report,
we compare the molecular features of
DM and psoriasis and apply molecular
profiling to aid in the diagnosis of an
ambiguous case of DM.
Our index case, a 32-year-old
woman, presented in June 2005 with the
3-month onset of well-demarcated viola-
ceous erythematous, scaling plaques on
her elbows, extensor forearms, dorsal
hands, lateral thighs, knees, and lower
legs, concerning for either psoriasis or
Gottron’s sign of DM (Figure 1a–c).
Diffuse erythema was also present on
her scalp and periungual areas, but she
did not display psoriatic nail changes,
geographic tongue, or heliotrope sign.
Antinuclear antibodies were positive
(titer 1:2,560) with a homogenous
pattern. Other antibodies including
anti-Jo1, SSA, SSB, anti-dsDNA, and
anti-centromere were negative. Given
her clinical ambiguity, a biopsy of one
of these psoriasis-like lesions on the knee
was performed. The biopsy demon-
strated regular epidermal acanthosis,
parakeratosis, mild, superficial peri-
vascular infiltrate, and dilated papillary
dermal vessels consistent with psoriasis
(Figure 1d). No interface dermatitis
was detected. However, a colloidal
iron stain revealed abundant mucin
throughout the dermis (Figure 1e),
which is unusual in psoriasis and
more consistent with DM. Given the
inconclusive results from traditional
histopathology, genome-wide expres-
sion analysis was applied to determineAccepted article preview online 3 June 2013; published online 27 June 2013
Abbreviation: DM, dermatomyositis
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